CLINICAL TRIALS PROFILE FOR PREVNAR 20

All Clinical Trials for PREVNAR 20

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00227188 ↗	Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.	Completed	Pfizer		2003-05-01	The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)
NCT00323557 ↗	Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients	Completed	Bayer	Phase 2	2004-06-01	The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
NCT00323557 ↗	Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients	Completed	M.D. Anderson Cancer Center	Phase 2	2004-06-01	The goal of this clinical research study is to see if Leukine(R) (sargramostim) improves the effectiveness of the pneumococcal vaccine, a medicine used to prevent pneumococcal pneumonia, in patients with chronic lymphocytic leukemia (CLL).
NCT00390130 ↗	Does the Order in Which Vaccines Are Administered Affect Pain Response?	Completed	The Hospital for Sick Children	Phase 4	2006-07-01	The objective of this study is to determine whether there should be a predetermined sequence recommended for administering these two vaccines, with the less painful vaccine being given first.
NCT00445484 ↗	Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	National Cancer Institute (NCI)	Phase 2	2007-01-01	RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.
NCT00445484 ↗	Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	Sidney Kimmel Comprehensive Cancer Center	Phase 2	2007-01-01	RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.
NCT00445484 ↗	Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma	Completed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	2007-01-01	RATIONALE: Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Vaccines may help the body build an effective immune response to kill cancer cells. Giving lenalidomide together with vaccine therapy may make a stronger immune response and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving lenalidomide together with vaccine therapy works in treating patients with relapsed or refractory multiple myeloma.

Clinical Trial Conditions for PREVNAR 20

Condition Name

Condition Name for PREVNAR 20
Intervention	Trials
Multiple Myeloma	3
Leukemia	2
Stage 0 Chronic Lymphocytic Leukemia	2
Stage I Chronic Lymphocytic Leukemia	2

Condition MeSH

Condition MeSH for PREVNAR 20
Intervention	Trials
Multiple Myeloma	5
Leukemia, Lymphocytic, Chronic, B-Cell	4
Leukemia	4
Neoplasms, Plasma Cell	4

Clinical Trial Locations for PREVNAR 20

Trials by Country

Trials by Country for PREVNAR 20
Location	Trials
United States	41
Poland	9
Finland	7
Spain	6
United Kingdom	4

Trials by US State

Trials by US State for PREVNAR 20
Location	Trials
Maryland	6
Florida	3
Texas	3
Arizona	2
Ohio	2

Clinical Trial Progress for PREVNAR 20

Clinical Trial Phase

Clinical Trial Phase for PREVNAR 20
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	8

Clinical Trial Status

Clinical Trial Status for PREVNAR 20
Clinical Trial Phase	Trials
Completed	11
Terminated	4
Recruiting	1

Clinical Trial Sponsors for PREVNAR 20

Sponsor Name

Sponsor Name for PREVNAR 20
Sponsor	Trials
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	5
National Cancer Institute (NCI)	4
Sidney Kimmel Comprehensive Cancer Center	4

Sponsor Type

Sponsor Type for PREVNAR 20
Sponsor	Trials
Other	23
Industry	10
NIH	5